Last reviewed · How we verify
NR082 injection
At a glance
| Generic name | NR082 injection |
|---|---|
| Sponsor | Wuhan Neurophth Biotechnology Limited Company |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase 3, Multicenter, Randomized, Double-Masked, Sham-Controlled Clinical Trial for Leber's Hereditary Optic Neuropathy (LHON) Associated With ND4 Mutation (PHASE3)
- Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated With ND4 Mutations (PHASE1, PHASE2)
- Gene Therapy Clinical Trial for the Treatment Of Leber's HereDitary Optic Neuropathy (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NR082 injection CI brief — competitive landscape report
- NR082 injection updates RSS · CI watch RSS
- Wuhan Neurophth Biotechnology Limited Company portfolio CI